Literature DB >> 1054288

The mechanism of action of methotrexate in cultured L5178Y leukemia cells.

W M Hryniuk.   

Abstract

This study investigates the relationships between the methotrexate (MTX)-induced purineless state and thymineless state and between the thymineless state and the kill of L5178Y cells. As an index of the thymineless state, we measured the effect of MTX on conversion of deoxyuridylate to thymidylate. This was measured as the rate of incorporation of tritiated deoxyuridine into DNA, but it was corrected for changes in incorporation of tritiated thymidine. Thus we derived the "calculated tritiated deoxyuridine rate." During the MTX treatment, the calculated tritiated deoxyuridine rate decreased rapidly at first and then more slowly. The slow 2nd-phase block was not reversed by hypoxanthine. As the 2nd-phase block deepened, the lymphoblasts continued to die (loss of cloning ability) but recovered the ability to incorporate tritiated thymidine into DNA. After 7 hr of MTX treatment, the kinetics of the 2nd-phase block in calculated tritiated deoxyuridine rate correlated closely with the kinetics of cell kill. Thus, MTX may inhibit dihydrofolate reductase enzyme, rapidly deplete S-phase L5178Y of reduced folates, and thus produce a purineless and thymineless state. As treatment continues, MTX intensifies the thymineless state, possibly by direct inhibition of thymidylate synthetase enzyme, and the cells die predominantly a thymineless death. The purineless state initially contributes to cell kill but later does not, possibly because it partially reverses spontaneously.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1054288

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation.

Authors:  Sophia Y Lunt; Vinayak Muralidhar; Aaron M Hosios; William J Israelsen; Dan Y Gui; Lauren Newhouse; Martin Ogrodzinski; Vivian Hecht; Kali Xu; Paula N Marín Acevedo; Daniel P Hollern; Gary Bellinger; Talya L Dayton; Stefan Christen; Ilaria Elia; Anh T Dinh; Gregory Stephanopoulos; Scott R Manalis; Michael B Yaffe; Eran R Andrechek; Sarah-Maria Fendt; Matthew G Vander Heiden
Journal:  Mol Cell       Date:  2014-12-04       Impact factor: 17.970

2.  Relative resistance to methotrexate by proliferating normal rabbit epidermal cells in vitro.

Authors:  R A Harper; B A Flaxman
Journal:  In Vitro       Date:  1981-05

3.  [Multidrug chemotherapy of osteogenic sarcoma (author's transl)].

Authors:  G Prindull
Journal:  Blut       Date:  1979-10

4.  Dipyridamole inhibits reversion by thymidine of methotrexate effect and increases drug uptake in Sarcoma 180 cells.

Authors:  S Cabral; S Leis; L Bover; M Nembrot; J Mordoh
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

Review 5.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

6.  Enhanced cytotoxicity with methotrexate in conjunction with hypoxanthine in L1210 cells in culture.

Authors:  C R Fairchild; J Maybaum; J A Straw
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717.

Authors:  N J Curtin; A L Harris; O F James; M F Bassendine
Journal:  Br J Cancer       Date:  1986-03       Impact factor: 7.640

Review 8.  Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management.

Authors:  Stergios Boussios; George Pentheroudakis; Konstantinos Katsanos; Nicholas Pavlidis
Journal:  Ann Gastroenterol       Date:  2012
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.